BACKGROUND: Human immunodeficiency virus (HIV) and malaria during pregnancy cause substantial perinatal mortality. As co-trimoxazole (CMX) protects children and HIV-positive adults against malaria, we compared the effectiveness of daily CMX with sulfadoxine-pyrimethamine intermittent preventive treatment (IPT-SP) on malaria risk in HIV-positive pregnant women in a Plasmodium falciparum-endemic African area. METHODS:From January 2009 to April 2011, we included in a randomized noninferiority trial all HIV type 1-infected pregnant women (≤28 weeks' gestation, CD4 count ≥200 cells/µL, hemoglobin level ≥7 g/L) in 19 health centers in Togo. Women were randomly assigned to daily 800 mg/160 mg CMX, or IPT-SP. The primary outcome was the proportion of malaria-free pregnancies. Other outcomes included malaria incidence, parasitemia, placental malaria, anemia, and infants' birth weight. RESULTS: Of 264 women randomly assigned to the CMX or IPT-SP group, 126 of 132 and 124 of 132, respectively, were included in the analysis. There were 33 confirmed cases of clinical malaria among 31 women in the CMX group, and 19 among 19 women in the IPT-SP group. Ninety-five of 126 (75.4%) women in the CMX group and 105 of 124 (84.7%) in the IPT-SP group remained malaria-free during their pregnancy (difference, 9.3%; 95% confidence interval [CI], -.53 to 19.1, not meeting the predefined noninferiority criterion). The incidence rate in intention-to-treat analysis was 108.8 malaria episodes per 100 person-years in CMX (95% CI, 105.4-112.2) and 90.1 in IPT-SP (95% CI, 86.8-93.4) (not significant). Prevalence of parasitemia was 16.7% in the CMX group vs 28% in the IPT-SP group (P = .02). Histology revealed 20.3% placental malaria in the CMX group vs. 24.6% in the IPT-SP group (not significant). Grade 3-4 anemia was more frequent in the CMX group (10% vs 4%; P = .008). No pregnant women died. Median birth weight was similar. CONCLUSIONS:Daily CMX was not noninferior to IPT-SP for preventing maternal malaria but safe and at least similar regarding parasitemia or placental malaria and birth outcomes. Clinical Trials Registration ISRCTN98835811.
RCT Entities:
BACKGROUND:Human immunodeficiency virus (HIV) and malaria during pregnancy cause substantial perinatal mortality. As co-trimoxazole (CMX) protects children and HIV-positive adults against malaria, we compared the effectiveness of daily CMX with sulfadoxine-pyrimethamine intermittent preventive treatment (IPT-SP) on malaria risk in HIV-positive pregnant women in a Plasmodium falciparum-endemic African area. METHODS: From January 2009 to April 2011, we included in a randomized noninferiority trial all HIV type 1-infected pregnant women (≤28 weeks' gestation, CD4 count ≥200 cells/µL, hemoglobin level ≥7 g/L) in 19 health centers in Togo. Women were randomly assigned to daily 800 mg/160 mg CMX, or IPT-SP. The primary outcome was the proportion of malaria-free pregnancies. Other outcomes included malaria incidence, parasitemia, placental malaria, anemia, and infants' birth weight. RESULTS: Of 264 women randomly assigned to the CMX or IPT-SP group, 126 of 132 and 124 of 132, respectively, were included in the analysis. There were 33 confirmed cases of clinical malaria among 31 women in the CMX group, and 19 among 19 women in the IPT-SP group. Ninety-five of 126 (75.4%) women in the CMX group and 105 of 124 (84.7%) in the IPT-SP group remained malaria-free during their pregnancy (difference, 9.3%; 95% confidence interval [CI], -.53 to 19.1, not meeting the predefined noninferiority criterion). The incidence rate in intention-to-treat analysis was 108.8 malaria episodes per 100 person-years in CMX (95% CI, 105.4-112.2) and 90.1 in IPT-SP (95% CI, 86.8-93.4) (not significant). Prevalence of parasitemia was 16.7% in the CMX group vs 28% in the IPT-SP group (P = .02). Histology revealed 20.3% placental malaria in the CMX group vs. 24.6% in the IPT-SP group (not significant). Grade 3-4 anemia was more frequent in the CMX group (10% vs 4%; P = .008). No pregnant women died. Median birth weight was similar. CONCLUSIONS: Daily CMX was not noninferior to IPT-SP for preventing maternal malaria but safe and at least similar regarding parasitemia or placental malaria and birth outcomes. Clinical Trials Registration ISRCTN98835811.
Entities:
Keywords:
HIV-positive pregnant women; P. falciparum malaria; co-trimoxazole; randomized controlled trial; sub-Saharan Africa
Authors: Paul Natureeba; Abel Kakuru; Mary Muhindo; Teddy Ochieng; John Ategeka; Catherine A Koss; Albert Plenty; Edwin D Charlebois; Tamara D Clark; Bridget Nzarubara; Miriam Nakalembe; Deborah Cohan; Gabrielle Rizzuto; Atis Muehlenbachs; Theodore Ruel; Prasanna Jagannathan; Diane V Havlir; Moses R Kamya; Grant Dorsey Journal: J Infect Dis Date: 2017-07-01 Impact factor: 5.226
Authors: Michelle E Roh; Stephen Shiboski; Paul Natureeba; Abel Kakuru; Mary Muhindo; Teddy Ochieng; Albert Plenty; Catherine A Koss; Tamara D Clark; Patricia Awori; Miriam Nakalambe; Deborah Cohan; Prasanna Jagannathan; Roly Gosling; Diane V Havlir; Moses R Kamya; Grant Dorsey Journal: J Infect Dis Date: 2017-12-19 Impact factor: 5.226
Authors: Krishanthi S Subramaniam; Jeff Skinner; Emil Ivan; Eugene Mutimura; Ryung S Kim; Catherine M Feintuch; Silvia Portugal; Kathryn Anastos; Peter D Crompton; Johanna P Daily Journal: PLoS One Date: 2015-04-30 Impact factor: 3.240
Authors: Roger D Wumba; Josué Zanga; Michel N Aloni; Kennedy Mbanzulu; Aimé Kahindo; Madone N Mandina; Mathilde B Ekila; Oussama Mouri; Eric Kendjo Journal: Malar J Date: 2015-02-18 Impact factor: 2.979
Authors: Vera Braun; Eva Rempis; Alexandra Schnack; Sarah Decker; John Rubaihayo; Nazarius Mbona Tumwesigye; Stefanie Theuring; Gundel Harms; Priscilla Busingye; Frank P Mockenhaupt Journal: Malar J Date: 2015-09-26 Impact factor: 2.979
Authors: Elisa Sicuri; Silke Fernandes; Eusebio Macete; Raquel González; Ghyslain Mombo-Ngoma; Achille Massougbodgi; Salim Abdulla; August Kuwawenaruwa; Abraham Katana; Meghna Desai; Michel Cot; Michael Ramharter; Peter Kremsner; Laurence Slustker; John Aponte; Kara Hanson; Clara Menéndez Journal: PLoS One Date: 2015-04-27 Impact factor: 3.240